CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Repository Corticotropin Injection +1 moredrug
Likely dose
Repository Corticotropin Injection 80 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02725177
NCT02725177N/ACompleted
CompareCT.gov

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

The Cleveland Clinic·interventional·Posted Mar 31, 2016·Updated Nov 14, 2023

In Brief

A clinical study evaluating Repository Corticotropin Injection and Repository Corticotropin Injection -Treatment Extension for Ocular Sarcoidosis and 2 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Sarcoidosis, Panuveitis, Anterior Uveitis
CountriesUnited States
CollaboratorsMallinckrodt

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 31, 2016
Enrollment StartJul 1, 2016
Primary CompletionDec 1, 2021
Study CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 10.3 years ago

Interventions

Repository Corticotropin Injectiondrug

Treatment with ACTHAR Gel for 24 weeks * Initial treatment with 80 units daily for ten days (induction phase) * Maintenance treatment with 80 units twice weekly (maintenance phase)

Repository Corticotropin Injection -Treatment Extensiondrug

24 open label extension permitted in subjects who respond to treatment